ImClone Systems Inc.

Public Subsidiary, Headquarters Location
180 Varick St., New York, NY 10014-4606, United States
(877)925-6631, (212)645-1405, (212)645-2054 fax, http://www.imclone.com

Primary SIC: Biological Products Except Diagnostic, Primary NAICS: Biological Product (except Diagnostic) Manufacturing
Description: Manufacturing: Developer of biologic treatments designed to address the medical needs of patients with cancer.

View this company profile - Now for a Limited Time, try Goliath Company Profiles
Free for 3 Days!

ImClone Systems Inc., News and Information

U.S. SEC eyes Nine Deals in Insider Trading Probe: Report
Reuters Hedgeworld; 12/10/2009; 776 words; ...Wyeth and Merck & Co. Inc.'s acquisition of Schering...including Abbott Laboratories Inc.'s acquisition of Advanced...Lilly & Co.'s buyout of ImClone Systems, the paper reported...retailer Best Buy Co. Inc.'s 2008 acquisition...

Cornerstone Therapeutics Appoints General Counsel.
Biotech Week; 11/25/2009; 705 words; ...General Counsel, Secretary, at ImClone Systems, Inc. where he led the legal and compliance...successfully structured and implemented ImClone's negotiated tender offer and...of CollaGenex Pharmaceuticals, Inc. where, from 2004-2008, he...

No Relief for Genzyme as APB Failure Dents Renal Franchise.
BIOWORLD Today; 11/19/2009; 1583 words; ...in pushing through acquisitions of MedImmune Inc. (by AstraZeneca plc) and ImClone Systems Inc. (by Eli Lilly & Co.), though attempts at putting Biogen Idec Inc. on the selling block have so far come to nothing...

Cancer Therapies - Global Market Opportunities.
M2 Presswire; 11/19/2009; 1505 words; ...developing and improving the healthcare system's screening systems, and abilities. Standard cancer treatments...Market Opportunities" by BizAcumen, Inc. Our reports are designed to be most...Initiates Phase III Trials of Cladribine - Imclone Awaits Approval for Erbitux from US Medicine...

Research and Markets: Cancer Therapies - Global Market Opportunities.
Business Wire; 11/19/2009; 1485 words; ...developing and improving the healthcare system's screening systems, and abilities. Standard cancer treatments...Market Opportunities" by BizAcumen, Inc. Our reports are designed to be most...Initiates Phase III Trials of Cladribine * Imclone Awaits Approval for Erbitux from US Medicine...

Why Purchase This Company Profile?

  • Sales prospecting
  • Competitive analysis
  • Vendor & supplier evaluation
  • Customer evaluation and analysis
  • Strategic planning

Need More Information?

Start a new search

Tell Us What You Think

Take our short survey to tell us what would make Goliath more valuable to you.

Add Your Company Information to Goliath
If your company does not appear in Goliath, click here to add it.

Update Your Company Information
If your company information has changed or is not correct,
click here to let us know.